Despite these limitations, the researchers believe the study confirmed the efficacy and safety of bimekizumab and brodalumab ...

Researchers have found Brukinsa to be a potentially safer alternative for patients with chronic lymphocytic leukemia.

Sellas Life Sciences has reported the multicentre Phase IIa trial data of a highly selective cyclin-dependent kinase 9 (CDK9) ...